<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765074</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO 2014-03</org_study_id>
    <nct_id>NCT02765074</nct_id>
  </id_info>
  <brief_title>Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis</brief_title>
  <acronym>REPAIR</acronym>
  <official_title>Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of 12 Months Subcutaneous Tocilizumab in Rheumatoid Arthritis Phase IV Prospective Multicentrique Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is a chronic inflammatory disease mediated by the production of
      several cytokines, which leads to the destruction of bone and cartilage tissue in multiple
      joints and to bone loss. Conventional radiographs (CR) are considered as the gold standard
      for diagnosis and follow up of joint changes in RA. But this method has low sensitivity to
      detect early erosive changes and is unable to evaluate periarticular bone loss.

      High Resolution peripheral QCT (HRpQCT) enables the detection of erosions less than 0.5 mm in
      width or depth at metacarpo-phalangeal (MCP) joints. Using 3-D high resolution analysis of
      cortical bone erosions, this one is also able to evaluate the volumes of erosion and the
      evolution under treatments IL6 (6- interleukin) plays a major role in inflammatory process
      and bone damages related to RA. Tocilizumab (TCZ) is a humanized anti-IL-6R monoclonal
      antibody, developed and investigated in several clinical trials in RA. This biotherapy, in
      association with methotrexate (MTX) or given in monotherapy, is efficient in RA with
      inadequate response to MTX or anti-TNF b (tumor necrosis factor). TCZ reduces dramatically
      systemic inflammation, structural progression and improves clinical symptoms and quality of
      life.

      Tocilizumab may help reducing bone erosions, periarticular osteopenia and systemic bone loss.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Anticipated">June 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone erosion change after 12 months of subcutaneous tocilizumab</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>changes of width measured by HRpQCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone erosion change after 12 months of subcutaneous tocilizumab</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>changes of depth measured by HRpQCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone erosion change after 12 months of subcutaneous tocilizumab</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>changes of volume measured by HRpQCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associated factors with erosion changes assessed by HRqQCT</measure>
    <time_frame>baseline, 3 months, 12 months</time_frame>
    <description>Number of participants with associated factors with erosion changes by HRpQCT (Associated therapeutic, clinical and biological response )ultrasound ...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 12 months of tocilizumab on bone density in the PR</measure>
    <time_frame>baseline, 12 months</time_frame>
    <description>Changes of Bone mineral density by DXA at the lumbar spine and proximal femur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Tocilizumab on synovitis/tenosynovitis assessed by US and agreement with disease activity scores</measure>
    <time_frame>Predictors baseline, 1 and 3 months of clinical remission and / or ultrasound at 6 and 12 months</time_frame>
    <description>Correlation Between clinical activity measured by various indices (Disease Activity Score 28, Clinical Disease Activity Iindex , Simplify Disease Activity Index , American College of Rheumatology - European League against Rheumatism: ACR EULAR) and ultrasound data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 12 months of tocilizumab on bone microarchitecture in the PR</measure>
    <time_frame>baseline, 12 months</time_frame>
    <description>changes of bone microarchitecture by tibia HRpQCT</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Roactemra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous tocilizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous tocilizumab</intervention_name>
    <description>162 mg subcutaneous, once a week during 12 months</description>
    <arm_group_label>Roactemra</arm_group_label>
    <other_name>Roactemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active RA, &lt; 10 years disease duration, diagnosed according to the ACR-EULAR 2010
             classification criteria

          -  DAS 28 superior or equal to 3.2 despite DMARD or biological treatment (other than
             tocilizumab)

          -  Superior or equal to one joint erosion at the right or left MCP 2, 3 on X-rays

          -  Oral corticosteroid ≤ 10 mg/day prednisone or equivalent stable for at least one month

          -  RA patients eligible to subcutaneous Tocilizumab monotherapy

        Exclusion Criteria:

          -  Treatment with zoledronic acid or denosumab (less than one year)

               -  Intra-articular injection of corticosteroids at the MCP in the previous three
                  months

               -  Tocilizumab contra-indications in accordance with SPC (Summary of Product
                  Characteristics) :Hypersensitivity to the active substance or to any of the
                  excipients Active, severe infections including active tuberculosis Diverticulitis
                  Active hepatic disease and hepatic Impairment including viral hepatitis Elevated
                  Alanine Aminotransferase or Aspartate Aminotransferase &gt;5×ULN Absolute neutrophil
                  count &lt; 0.5 × 10 exp 9 /L Platelet count &lt; 50×10 exp 3 /μL,

        General:

          -  Absence of informed consent

          -  Prior or planned joint surgery of the hands which might impact the interpretation of
             imaging assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SALLIOT Carine, MD</last_name>
    <role>Study Director</role>
    <affiliation>CHR ORLEANS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LESPESSAILLES Eric, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR ORLEANS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CANTAGREL Alain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU TOULOUSE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHAPURLAT Roland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU LYON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MAROTTE Hubert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL NORD SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SALLIOT Carine, MD</last_name>
    <phone>33 2 38 22 99 22</phone>
    <email>carine.salliot@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DESPUJOLS Aurélie</last_name>
    <phone>33 2 38 74 40 71</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Edouard HERIOT</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>CHAPURLAT Roland, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR d'ORLEANS</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>SALLIOT Carine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Nord CHU de SAint ETIENNE</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MAROTTE Hubert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline RUYSSEN-WITRAND, Dr</last_name>
      <email>ruyssen-witrand.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Adeline RUYSSEN-WITRAND, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005 Dec;90(12):6508-15. Epub 2005 Sep 27.</citation>
    <PMID>16189253</PMID>
  </reference>
  <reference>
    <citation>Stach CM, Bäuerle M, Englbrecht M, Kronke G, Engelke K, Manger B, Schett G. Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum. 2010 Feb;62(2):330-9. doi: 10.1002/art.27252.</citation>
    <PMID>20112404</PMID>
  </reference>
  <reference>
    <citation>Fouque-Aubert A, Boutroy S, Marotte H, Vilayphiou N, Bacchetta J, Miossec P, Delmas PD, Chapurlat RD. Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT. Ann Rheum Dis. 2010 Sep;69(9):1671-6. doi: 10.1136/ard.2009.114512. Epub 2010 Jun 4.</citation>
    <PMID>20525847</PMID>
  </reference>
  <reference>
    <citation>Ellouz R, Chapurlat R, van Rietbergen B, Christen P, Pialat JB, Boutroy S. Challenges in longitudinal measurements with HR-pQCT: evaluation of a 3D registration method to improve bone microarchitecture and strength measurement reproducibility. Bone. 2014 Jun;63:147-57. doi: 10.1016/j.bone.2014.03.001. Epub 2014 Mar 12.</citation>
    <PMID>24614646</PMID>
  </reference>
  <reference>
    <citation>Møller Døhn U, Boonen A, Hetland ML, Hansen MS, Knudsen LS, Hansen A, Madsen OR, Hasselquist M, Møller JM, Østergaard M. Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis. 2009 Oct;68(10):1585-90. doi: 10.1136/ard.2008.097048. Epub 2008 Nov 19.</citation>
    <PMID>19019887</PMID>
  </reference>
  <reference>
    <citation>Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Stach C, Schett G. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis. 2011 Sep;70(9):1587-93. doi: 10.1136/ard.2010.148395. Epub 2011 May 27.</citation>
    <PMID>21622765</PMID>
  </reference>
  <reference>
    <citation>Døhn UM, Ostergaard M, Bird P, Boonen A, Johansen JS, Møller JM, Hansen MS. Tendency towards erosive regression on magnetic resonance imaging at 12 months in rheumatoid arthritis patients treated with rituximab. Ann Rheum Dis. 2009 Jun;68(6):1072-3. doi: 10.1136/ard.2008.098962.</citation>
    <PMID>19435723</PMID>
  </reference>
  <reference>
    <citation>Døhn UM, Ejbjerg B, Boonen A, Hetland ML, Hansen MS, Knudsen LS, Hansen A, Madsen OR, Hasselquist M, Møller JM, Ostergaard M. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis. 2011 Feb;70(2):252-8. doi: 10.1136/ard.2009.123729. Epub 2010 Oct 26.</citation>
    <PMID>20980282</PMID>
  </reference>
  <reference>
    <citation>Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Schett G. Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study. Ann Rheum Dis. 2013 Mar;72(3):396-400. doi: 10.1136/annrheumdis-2011-201075. Epub 2012 May 14.</citation>
    <PMID>22586162</PMID>
  </reference>
  <reference>
    <citation>Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010 Jan;62(1):33-43. doi: 10.1002/art.25053.</citation>
    <PMID>20039425</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>subcutaneous tocilizumab</keyword>
  <keyword>High Resolution peripheral QCT (HR-pQCT)</keyword>
  <keyword>bone erosion</keyword>
  <keyword>bone microarchitecture</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

